Get notified when TYRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTyra Biosciences expands board to 10 members, appoints former Acceleron CEO Habib Dable
Filed April 17, 2026 · Period ending April 16, 2026 · ~1 min read
Key Changes
-
medium
Board expanded from nine to ten directors with appointment of Habib J. Dable as Class II director, term expiring at 2026 annual meeting. Dable previously led Acceleron Pharma through its acquisition by Merck in 2021.
Item 5.02 verify on EDGAR → -
medium
New director brings pharmaceutical industry expertise from leadership roles at Bayer and Acceleron, currently serves as advisor at RA Capital Management and on multiple biotech boards.
Item 5.02 verify on EDGAR → -
low
Dable granted options to purchase 44,400 shares at fair market value, vesting monthly over 36 months, plus standard non-employee director cash compensation.
Item 5.02 verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.
Partner
Trade TYRA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify